Case Study 2: Production of important building block for cardiovascular drug
Current Production
Highlights:
- 6 steps, difficult isolation and purification, <20% overall yield
- Product is highly volatile and unstable
- Only one enantiomer readily available (unnatural aspartic acid is very expensive)
Radiant Production
Highlights:
- 5 steps, >99.0% ee, >99.0% chemical purity
- Final tosylate salt is highly crystalline, highly stable, and easy to handle and purify
- Both enantiomers are readily available (both enantiomers of malic acid are inexpensive)
- Demonstrated on >100 kg scale in pilot plant